

CURRICULUM VITAE

Z. NICHOLAS ZAKOV, MD, FACS
(ZVETAN NIKOLOV ZAKOV, MD, FACS)

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.
690 White Pond Drive, Suite 120; Akron, Ohio 44320
3401 Enterprise Parkway, Suite 300; Beachwood, Ohio 44122
4690 Munson Street NW; Canton, Ohio 44718
340 Oxford Street, Suite 210; Dover, Ohio 44622
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
15299 Bagley Road, Suite 200; Middleburg Heights, Ohio 44130
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136
170 North Road NE; Warren, Ohio 44483
4350 Crocker Road, Suite 200; Westlake, Ohio 44145
5390 Belmont Avenue; Youngstown, Ohio 44505
708 N Jefferson Street; New Castle, Pennsylvania 16101

TELEPHONE 216-831-5700

WEBSITE www.retina-doctors.com

EDUCATION

High School Cleveland Heights High School
Cleveland, OH
1962

College Kenyon College
Gambier, OH
1962–66, BA

Medical School Columbia University
College of Physicians and Surgeons
New York, NY
1966–70, MD

POSTGRADUATE TRAINING

Internship Surgical Internship
Columbia Presbyterian Medical Center
New York, NY
1970–1971

<i>Residency</i>	Ophthalmology Cleveland Clinic Foundation Cleveland, OH 1973–1976
<i>Fellowships</i>	Retinal & Vitreous Diseases Bascom Palmer Eye Institute University of Miami Miami, FL 1976–1977
	Retinal & Vitreous Diseases Clinical & Experimental Pathology Howe Laboratory of Ophthalmology Massachusetts Eye & Ear Infirmary Harvard Medical School Boston, MA 1977–1978

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio, Colorado, and Pennsylvania

Diplomate, American Board of Ophthalmology 1977

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, Inc.	1990–
Practice limited to Retinal Diseases and Surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD	
Head, Section of Retinal & Vitreous Disease Department of Ophthalmology Cleveland Clinic Foundation Cleveland, OH	1986–1990
Staff Member Retinal and Vitreous Section, Department of Ophthalmology Cleveland Clinic Foundation Cleveland, OH	1978–1990

Associate Staff Member Department of Ophthalmology Cleveland Clinic Foundation Cleveland, OH	1976–78
Fellow of the Royal Society of Medicine	2010–2013
Corporate Consultant (unpaid) Synergetics, Inc. O’Fallon, MO	2006–2010
Lecturer Ophthalmic Pathology Section Case Western Reserve University Basic Science Course in Ophthalmology	1980–84
Consultant National Institute for Occupational Safety and Health Epidemiologic Field Study of the Incidence of Uveal Melanoma in a Population of Chemical Workers	1978
Lecturer Ophthalmic Pathology Section Harvard Basic Science Course in Ophthalmology	1977–82
Diplomate Lancaster Basic Course in Ophthalmology	1973
General Medical Officer U.S. Public Health Service, Indian Health Service Belcourt, ND Rank at retirement: Lieutenant Commander	1971–73
Visiting Student Institute of Ophthalmology and Moorfields Eye Hospital, London, England	1970

ACADEMIC APPOINTMENTS

Clinical Professor of Ophthalmology, 2006–2017 (Retired)
Associate Clinical Professor of Ophthalmology, 1997–2006
Assistant Clinical Professor of Ophthalmology, 1990–1997
Case Western Reserve University School of Medicine
Cleveland, Ohio

PROFESSIONAL SOCIETIES AND COMMITTEES

Retina Society

By-laws Committee Chairman, 2002–2010

Credentials Committee, 1986–89

Chairman of Committee, 1988–89

Program Co-Chairman, 1985

American Society of Retina Specialists (formerly the Vitreous Society)

Representative to the American Academy of Ophthalmology Council, 2006–2012

Liaison to the American Retina Foundation, 2002–2006

Practice Management Committee Founder and Chairman, 1999–2002

Emeritus Director, 2001–2008

Awards Committee Founder and Chairman, 1996–2006

By-laws Committee Chairman, 1991–96

President, 1987–88

Board of Directors, 1985–2008

Program Co-Chairman, 1985, 1986

American Academy of Ophthalmology Council

Co-chair, Great Lakes section, 2007–2009

American Board of Ophthalmology

Associate Examiner, 1986–2010

Cleveland Ophthalmological Society

President, 1992–93

President-Elect, 1991–92

Chairman, Education Program Committee, 1991–92

Executive Committee, 1991–94

Peer Review Committee, 1991–92

American Society of Ocular Trauma (formerly the US Eye Injury Registry)

Emeritus Director, 2002–2008

Board of Directors, 2002–2008

Founding President, 2002

American Eye Study Club

Charitable Foundation Committee, 2002–2006

Emeritus Member, 1992–

Member, 1982–1992

Cleveland Clinic

Program Co-Chairman, Dedicatory Meeting of new Department of Ophthalmology, 1986

Hillcrest Hospital

Head, Section of Retinal/Vitreous Diseases and Surgery, 1990–2008

Diabetes Education Committee, 1991–1999

University Hospitals of Cleveland, Department of Ophthalmology and Visual Sciences

Member, Appointments, Promotions, and Tenure Committee, 1998–1999, 2007–2009

Case Western Reserve University School of Medicine
Member, Advisory Board for Macular Degeneration Research, 2008–2012

Cleveland Eye Bank
35th Anniversary Campaign Committee

Ohio Eye Injury Registry
Scientific Co-Director, 1994–1998

United States Eye Injury Registry
President, 1998–2003
President-Elect, 1996–1998
By-laws Committee, 1997–2008
Executive Committee, 1996–2002
Nominating Committee, 1996–2002
Board of Directors, 1994–2008

South East European Ophthalmological Society (formerly the Balkan Ophthalmological Society)
Founding Member, 1998
By-laws Committee, 1998–2002

International Society of Ocular Trauma
By-laws Committee, 2000–2008
International Scientific Committee, International Symposium on Ocular Trauma, 2006, Rome, Italy
Organizing Committee, 2003 Meeting, Sopron, Hungary

Eye Fly Club
Naming Co-Chairman

Visionary Practitioner Recognition Award Program, Pfizer Ophthalmics
Co-Chairman, 2003–2004

Mediterranean Retina Meeting, 2004–
Co-Founder and Co-Director with Dr. Murat Oncel

Ayhan Sahenk Award for Vitreoretinal Excellence
Creator, in conjunction with the Sahenk Family
First awarded in 2004 at the Mediterranean Retina Meeting

American Journal of Ophthalmology
Scientific Reviewer

American Society of Retina Specialists (formerly the Vitreous Society) Online Journal
Editorial Board, 1998–2008

Cleveland Clinic Journal of Medicine, Editorial Committee
Book Review Editor, 1983–89

Ocular Surgery News
Book Review Editor, 1989–2004

Ophthalmic Lasers and Surgery
Scientific Reviewer

Ophthalmology
Scientific Reviewer

Retina-Vitreus (Turkish Retinal Journal)
Editorial Board, 1993–2004

HONORS AND AWARDS

Retina Hall of Fame	
Founding Board of Directors	2017
Secretary-Treasurer, Board of Directors	2017-
Charter Member	
25-year Service Award, Hillcrest Hospital	2015
Ayhan Sahenk Award for Vitreoretinal Excellence	2014
Mediterranean Retina Board Friendship Award for longstanding contribution and collaboration	2010
Turkish Ophthalmology Society	
Fourth Mediterranean Retina Meeting	
American Retina Foundation	2009
Award in recognition of extensive work with the Foundation and of outstanding contributions as a founding member and as past president	
Appreciation Award for Dedication and Service	2008
Council of the American Academy of Ophthalmology	
Nikos Kazantzakis Medal of the University of Crete, Greece	2007
On the occasion of the 10 th Aegean Retina Meeting	
Albert D. Ruedemann, Jr. Lecturer	2005
American Eye Study Club	
Honorary citizen of the city of Dubrovnik, Croatia	2005
Honorary member of the Union of Bulgarian Ophthalmologists	2004
Ambassador of Goodwill of Israel, Israel Ministry of Tourism	2003
Leadership Award, American Society of Ocular Trauma	2002
Senior Honor Award, Vitreous Society (American Society of Retinal Specialists)	2001
Public Service Award, Ohio Ophthalmological Society,	1998, 1999
Honor Award, American Academy of Ophthalmology	1998
Vitreous Society (American Society of Retinal Specialists) Honor Award	1998
Best Doctors in America	1996–2015
Excellence in Teaching Award, Mt. Sinai Medical Center	1991
Vitreous Society (American Society of Retinal Specialists) Leadership Award	1987
American Board of Ophthalmology-Certificate of Appreciation for Participation as an Associate Examiner	1986–91
Heed Ophthalmic Foundation Fellowship	1976–77
Alvin Behrens Memorial Prize in Ophthalmology	1970
Robert Bowen Brown, Jr. Prize in biology	1966
Summa cum laude, highest honors in biology	1966
Phi Beta Kappa	1965
Lubrizol Corporation Chemistry Prize	1962

MEMBERSHIPS

American Academy of Ophthalmology
American College of Surgeons

American Eye Study Club
American Society of Ocular Trauma
American Society of Retinal Specialists (formerly the Vitreous Society)
U.S. Eye Injury Registry
Retina Society
Macula Society
Aspen Retinal Detachment Society
Ohio Ophthalmological Society
Cleveland Ophthalmological Society
Mediterranean Retina Group
Turkish American Ophthalmological Society
Aegean Retina Meeting Group
International Society of Ocular Trauma
Schepens International Society
Macular Degeneration International
Pan-American Association of Ophthalmology
South East European Ophthalmological Society
Eye Fly Club
European Vitreoretinal Society

HOSPITAL AFFILIATIONS

University of Pittsburgh Medical Center (UPMC); Pittsburgh, Pennsylvania

RESEARCH ACTIVITIES

NIH-funded Grants

Collaborative Ocular Melanoma Study

Principal Investigator, Retina Associates of Cleveland Center, 1997–2003

Co-investigator, Cleveland Clinic Center, 1987–2003

Home vision monitoring in AREDS2 for progression to neovascular age-related macular degeneration

Co-investigator, 2011–2013

Age-Related Eye Disease Study 2

Co-investigator, 2006–2012

*Standard Care vs. **C**orticosteroid for **R**etinal Vein Occlusion (**SCORE**) Study*

Co-investigator, 2004–2009

Diabetic Retinopathy Clinical Research Network Protocol #1A. A pilot study of laser photocoagulation for diabetic macular edema.

Co-investigator, 2003–

Complications of Age-related Macular Degeneration Prevention Trial
Co-investigator, 1998–

Choroidal Neovascularization Prevention Trial – Pilot Study
Co-investigator, 1995–2001

Other National Clinical Trials

Choroidal indeterminate melanocytic lesions prompt vs deferred treatment—a multi center randomized study
Principal Investigator, 2008

Hydrokinetic retinal manipulation using the liquid and viscous fluorocarbon perfluorophenanthrene
Principal Investigator, 1993–94

Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration
Co-investigator, 2018–

Phase III randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and lucentis® in subjects with neovascular age-related macular degeneration
Co-investigator, 2018–

Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)
Co-investigator, 2017–

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)
Co-investigator, 2016–

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration
Co-investigator, 2015–2018

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration
Co-investigator, 2015–2016

An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)
Co-investigator, 2015–2017

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–2017

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2013–2017

Phase 2 multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (MacTel)

Co-investigator, 2013–

Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)

Co-investigator, 2012–2014

Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (Mactel)

Co-investigator, 2011–2016

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy (MAHALO)

Co-investigator, 2011–2013

Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration

Co-investigator, 2010–2011

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Geographic Atrophy Treatment Evaluation (GATE) Study (Alcon)

Co-investigator, 2009–2012

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008–2012

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to

assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy

Co-investigator, 2008–2010

Natural History of Geographic Atrophy Progression (GAP) Study (Alcon)

Co-investigator, 2008–2009

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–2012

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007–2010

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC): Comparison of PHP (Preferential Hyperacuity Perimetry) with supervised Amsler grid in detecting neovascular AMD in eyes at high risk for CNV

Co-investigator, 2007–2009

OMEGA: a randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2009

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2009

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

Co-investigator, 2007–2008

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)

Co-investigator, 2007–2008

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007–2008

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007

Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane

Co-investigator, 2006–2010

Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization

Co-investigator, 2006–2010

SIRIUS: A 2-year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN 211745 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2006–2008

Study of the efficacy and safety of intravitreal injection of Macugen for neovascular lesions of AMD with recent onset

Co-investigator, 2006–2008

Sirion randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2006–2007

A multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients

Co-investigator, 2006–2007

A Phase IIIB, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)

Co-investigator, 2006–2007

Protocol FVF3426g (HORIZON): An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal

neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study

Co-investigator, 2006–2007

Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement

Co-investigator, 2006

Natural history study of macular telangiectasia (MacTel)

Co-investigator, 2005–

The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography

Co-investigator, 2005–2011

A 6-month, Phase III, multicenter, masked, randomized, sham-controlled trial (with 6-month open-label extension) to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following branch retinal vein occlusion or central retinal vein occlusion

Co-investigator, 2005–2007

RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)

Co-investigator, 2005–2007

Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration

Co-investigator, 2005–2007

Phase 3 assessment of the safety and efficacy of two doses of dexamethasone vs. sham treatment with the dexamethasone posterior segment drug delivery system applicator in patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion.

Co-investigator, 2005–2007

Eyetech 1012: A Phase 4, randomized, active controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen® given every 6 weeks for 102 weeks plus sham photodynamic therapy (PDT), to Macugen plus PDT® with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Co-investigator, 2005–2007

An open label study for the evaluation of tolerability of four dose levels of Cand5 administered by single intravitreal injection in patients with wet age-related macular degeneration

Co-investigator, 2005–2007

A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema

Co-investigator, 2005–2006

Veritas: A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2005–2006

Phase IV study of daily dosing (vs. previous “on demand”) of Cialis vs. Viagra vs. placebo and its effect on visual functioning in healthy males or those with mild erectile dysfunction

Co-investigator, 2005–2006

A Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia

Co-investigator, 2005–2006

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema

Co-investigator, 2004–2010

Anecortave Acetate Risk-Reduction Trial (AART)

Co-investigator, 2004–2008

A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment

Co-investigator, 2004–2006

Eyeteck 1011B: A Phase II randomized, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to central retinal vein occlusion)

Co-investigator, 2004–2006

A randomized, single-masked, multicenter, Phase 2 evaluation of the effect of photodynamic therapy using verteporfin (Visudyne® Therapy) in combination with intravitreal injection of either 0 mg, 1 mg, or 4 mg of triamcinolone acetonide in occult subfoveal and minimally

classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): Visudyne with Intravitreal Triamcinolone Acetonide (VisTA) Trial
Co-investigator, 2004–2006

A Phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration(ANCHOR)
Co-investigator, 2003–2006

The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy
Co-investigator, 2003–2005

Intravitreal Steroid Injection Studies (ISIS)
Co-investigator, 2002–2006

Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study. A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert™, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema
Co-investigator, 2001–2007

Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with AMD
Co-investigator, 2001–2006

Protein Kinase C β Inhibitor – Diabetic Retinopathy Study 2
Co-investigator, 2001–2006

Oculex Study: A Phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS®) in the treatment of persistent macular edema
Co-investigator, 2001–2003

Evaluation of efficacy and safety of a sub-Tenon's injection of anecortave acetate sterile suspension versus placebo in patients with exudative age-related macular degeneration (AMD) following treatment with photodynamic therapy (PDT) using Visudyne™
Co-investigator, 2000–2001

Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection
Co-investigator, 1999–2000

Protein Kinase C β Inhibitor – Diabetic Macular Edema Study and Diabetic Retinopathy Studies

Co-investigator, 1998–2002

An evaluation of safety and duration of efficacy of anecortave acetate sterile suspension (30 mg, 15 mg or 3 mg) versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with age-related macular degeneration

Co-investigator, 1998–2001

Perfluron™ (perfluoro-n-octane) for use in the treatment of complicated retinal detachment

Co-investigator, 1995–1996

Vitraxe™ for Vitreous Hemorrhage Study

Co-investigator, 1998–1999

Age-related Macular Degeneration / Thalidomide Study

Co-investigator, 1995–2000

Protocol SO14297 Interferon Alfa-2a

Co-investigator, 1994–96

Alfa-interferon treatment of choroidal neovascularization

Co-investigator, 1993–96

Oculon Study. Evaluation of the efficacy of OC-2 in the inhibition of cataract formation associated with vitrectomy surgery

Co-investigator, 1993–94

SCIENTIFIC PRESENTATIONS

Over 320 lectures, posters, and presentations 1974–

VISITING PROFESSOR AND LECTURER

Mediterranean Retina Meeting VII 2017

Sorrento, Italy

Planning Committee

Red Lodge Forum for Provocative Issues 2014

Red Lodge, Montana

Speaker, *Unintended Consequences*

Mediterranean Retina Meeting VI 2014

Izmir, Turkey

Planning Committee

St. Louis University Department of Ophthalmology 2014

St. Louis, Missouri

St. Louis Ophthalmological Society	2014
Croatian Ophthalmology Congress Dubrovnik, Croatia	2010
Vitreoretinal Symposium IV Lodz, Poland	2010
Mediterranean Retina Meeting III Antalya, Turkey Organizer	2008
Ravenna International Courses in Ophthalmology Ravenna, Italy	2007
University of Ljubljana Ljubljana, Slovenia	2007
International Retina Congress Tenth Anniversary of the Retina Institute of Karnataka Bangalore, India Chief Discussant	2006
Mediterranean Retina Meeting II Antalya, Turkey Organizer	2006
Vitreoretinal Symposium II Lodz, Poland	2005
XIII Afro-Asian Council of Ophthalmology Istanbul, Turkey	2004
Mediterranean Retina Meeting I Antalya, Turkey Organizer	2004
Seventh Congress of the Union of Bulgarian Ophthalmologists Plovdiv, Bulgaria Keynote Speaker	2004
The 6th International Advanced Vitreo Retinal Surgery Course (6th IAVRSC) and Silver Jubilee Celebrations of Sankara Nethralaya Chennai, India Keynote Speaker	2003
Vitreoretinal Symposium I Lodz, Poland	2003
Goldschleger Eye Institute Annual Meeting Tel Aviv, Israel	2003
Thirty-fifth Panhellenic Ophthalmological Congress Halkidiki, Greece	2002
XIII th European Congress of Ophthalmology Istanbul, Turkey	2001
Second Congress of the Union of Bulgarian Ophthalmologists Borovets, Bulgaria Keynote Speaker	1999

Harkness Eye Institute, Department of Ophthalmology Columbia University College of Physicians & Surgeons New York, New York	1998
Thirty-first Panhellenic Ophthalmological Congress Halkidiki, Greece	1998
University of Istanbul, Cerrahpasa Medical School Istanbul, Turkey	1998
V Tubingen Detachment Course Plovdiv, Bulgaria	1993
Gazi University Ankara, Turkey	1993
Youngstown Ophthalmology Group	1993
University of Akron Akron, Ohio	1993
University of South Florida Tampa, Florida	1992
Turkish Ophthalmological Society Annual Meeting Ankara, Turkey	1990
Buffalo Ophthalmological Society University of Buffalo, Buffalo, NY	1989
St. Francis Medical Center Pittsburgh, Pennsylvania	1989
University of Istanbul, Cerrahpasa Medical School Istanbul, Turkey	1989
Aegean University Izmir, Turkey	1989
West Virginia University, Department of Ophthalmology Morgantown, West Virginia	1989
Peruvian Ophthalmology Society	1984
Venezuelan Ophthalmology Society	1982
Caylor-Nickel Clinic Bluffton, Indiana	1980
Youngstown Ophthalmology Group	1980
Erie Ophthalmological Society	1979

MISCELLANEOUS CHARITIES, ACTIVITIES, AND BOARDS

Alumni activities, Kenyon College
Extern Sponsor Program, 1978–2013
Alumni Association Distinguished Service Award, 2006
Class of '66 Special Gift Co-Chairman
Gift Chair, 35 th Reunion
25 th , 30 th , and 35 th Reunions Committee
Tourette Syndrome Association of Ohio, Inc.
Vice President, 1987–88

Board of Trustees, 1986–89
Zakov Family Scholarship
Established 2002 at Kenyon College, Gambier, Ohio
Zakov Family Scholarship
Established 1997 at Ferris State University, Big Rapids, Michigan
The North Hanna Foundation Educational Fund
Board of Trustees, 1995–2005
American Eye Study Club Foundation
Board of Trustees, 2003–2018
American Society of Retina Specialists Foundation (formerly the Vitreous Society Foundation)
President, 2006–2009
Vice President, 2000–2006
Founding Donor, 2005
Ad Hoc Committee, 1999–2005
Board of Trustees, 1998–2006
Roundtable Book Club
Member, 2014–
Pasteur Club
President, 2016–2017
Member, 2013–
Red Lodge Forum for Provocative Issues
Member, 2012–
Palm Island Philosophical Society (PIPS)
Co-founder, 2012
Member, 2012–
Docent, Body Worlds II
Great Lakes Science Center, Cleveland, Ohio, 2005
The Book Review Depot – a blog for book reviews (<http://bookreviewdepot.blogspot.com>)
Founder, 2011
NCI Book Club
Member, 2010–2016
Philosophical Club of Cleveland
Member, 2007-2017
Secretary, 2010–2011
Treasurer, 2009–2010
Travelers' Century Club
Member, 2008–
The Union Club
Member, 2008–
Donor: Cleveland Play House, Cleveland Orchestra

PUBLICATIONS

Articles and Chapters

1. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 report no. 17. *Ophthalmology*. 2018 Aug 22. pii: S0161-6420(18)31752-4. doi: 10.1016/j.ophtha.2018.08.017. [Epub ahead of print]
2. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
3. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The association of statin use with cataract progression and cataract surgery: The AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
4. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol*. 2015 Sep;133:1022-1029.
5. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015 Apr;159:659-666.
6. Danis RP, Domalpally A, Chew EY, et al; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013;54:4548-4554.
7. Aronow ME, Adamus G, Abu-Asab M, Wang Y, Chan CC, Zakov ZN, Singh AD. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. *Surv Ophthalmol* 2012;57:558-564.
8. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology* 2011;118:2453-2460.

9. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology* 2011;118:2461-2467.
10. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
11. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010;117:1134-1146.
12. Hood CT, Budd GT, Zakov ZN, Singh AD. Male breast carcinoma metastatic to the choroid: report of 3 cases and review of the literature. *Eur J Ophthalmol* 2011;21:459-467.
13. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
14. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
15. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
16. Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.
17. Boldt HC, Melia BM, Liu JC, Reynolds SM; Collaborative Ocular Melanoma Study Group. I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30. *Ophthalmology* 2009;116:106-115.
18. Collaborative Ocular Melanoma Study Group, Boldt HC, Byrne SF, Gilson MM, Finger PT, Green RL, Straatsma BR, Simpson ER, Hawkins BS. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular

- Melanoma Study: COMS report no. 29. *Ophthalmology* 2008;115:1390-1397. Epub 2008 Feb 11.
19. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
 20. Qian Y, Zakov ZN, Schoenfield L, Singh AD. Iris melanoma arising in iris nevus in oculodermal melanocytosis. *Surv Ophthalmol* 2008;53:411-415.
 21. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
 22. Collaborative Ocular Melanoma Study Group. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27. *Ophthalmology* 2007;114:1363-1371. Epub 2007 Mar 6.
 23. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
 24. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
 25. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2006; 113:1974-1986.
 26. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1432-1444.
 27. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol* 2006;124:1684-1693.
 28. Melia M, Moy CS, Reynolds SM, Hayman JA, Murray TG, Hovland KR, Earle JD, Kurinij N, Dong LM, Miskala PH, Fountain C, Cella D, Mangione CM; Collaborative Ocular Melanoma Study-Quality of Life Study Group. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the

- Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. *Arch Ophthalmol* 2006;124:226-238.
29. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol* 2005;123:1639-1643.
 30. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. *Arch Ophthalmol* 2005;123:601-604.
 31. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004;351:2805-2816.
 32. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
 33. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
 34. Mobley RY, Moy CS, Reynolds SM, Diener-West M, Newhouse MM, Kerman JS, Hawkins BS; Collaborative Ocular Melanoma Study Group. Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study. *Clin Trials* 2004;1:377-386.
 35. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004;1:91-107.
 36. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 2004;111:966-976.
 37. Gurelik G, Coney JM, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *Ophthalmic Surg Lasers Imaging* 2004;35:94-102.

38. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
39. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 2003;121:1163-1171.
40. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 2003;121:1156-1162.
41. Melia M, Moy CS, Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM, The Collaborative Ocular Melanoma Study-Quality Of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 2003;121:1010-1020.
42. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
43. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. *Ophthalmology* 2003;110:971-978.
44. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P, The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.
45. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE, Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.

46. Scott IU, Murray TG, Flynn HW Jr, Feuer WJ, Schiffman JC, Perfluoron Study Group. Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane. *Ophthalmology* 2002;109:1828-1833.
47. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002;22:143-52.
48. Hollick RA, Reynolds SM, the Collaborative Ocular Melanoma Study Group. Adding centers to boost subject accrual: a case study for a rare condition. *Applied Clinical Trials* 2002;11 (10):54-59.
49. Diener-West M, Hawkins B, the Collaborative Ocular Melanoma Study Group. Changing current practice. Implementing large multicenter trials for a rare condition. *Applied Clinical Trials* 2002;11(9):48-54.
50. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 2002;109:2197-2206. (Correction: *Ophthalmology* 2004; 111:1514)
51. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials – TAP report No. 5. *Arch Ophthalmol* 2002;120:1307-1314.
52. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002;22:143-152.
53. Byrne SF, Marsh MJ, Boldt HC, Green RL, Johnson RN, Wilson DJ. Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study COMS Report No. 13. *Ophthalmic Epidemiol* 2002;9:11-27.
54. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. *Controlled Clin Trials* 2001;22:526-537.
55. Zakov ZN. Foreword, in Kuhn F, Pieramici DJ (eds.), *Ocular Trauma: Principles and Practice*. Thieme: New York, 2002, pp xiii-xiv.
56. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 2001;119:969-982.

57. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 2001;119:951-965.
58. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 2001;131:788-791.
59. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 2001;108:348-366.
60. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 2001;119:670-676.
61. Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; The Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding. Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 2001;22:248-262.
62. Scott IU, Moy CS, Murray TG for the COMS Group. Update on the Collaborative Ocular Melanoma Study (COMS) for the comprehensive ophthalmologist. *Comp Ophthalmol Update* 2000;1:185-191.
63. Choroidal Neovascularization Prevention Trial Research Group. Laser-induced drusen reduction improves visual function at 1 year. *Ophthalmology* 1999;106:1367-1373.
64. COMS Quality of Life Study Group. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. *Ophthalmic Epidemiol* 1999;6:5-17.
65. Purohit SS, Matthews GP, Zakov ZN. Pneumatic buckle for the repair of primary rhegmatogenous retinal detachment. *Ophthalmic Lasers and Surgery* 1999;30:509-512.
66. Meffert S, Peyman GA, the Vitreous Study Group. Intraoperative complications of perfluoroperhydrophenanthrene: subretinal perfluorocarbon, retinal slippage and residual perfluorocarbon. *Can J Ophthalmol* 1999;34:272-280.
67. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophth Nurs Technol* 1999;Part I 18:143-149, Part II 18:219-232.

68. Cruickshanks KJ, Fryback DG, Nondahl DM, Robinson N, Keesey U, Dalton DS, Robertson DM, Chandra SR, Mieler WF, Zakov ZN, Custer PL, Del Priore LV, Albert DM. Treatment choice and quality of life in patients with choroidal melanoma. *Arch Ophthalmol* 1999;117:461-467.
69. Pendergast SD, Zakov ZN, Novak MA. Lasers in vitreous surgery. In Singerman LJ, Coscas G (eds). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine, pp 153-164, 1999.
70. Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. *Ophthalmology* 1998;105:1364-1372.
71. Tomsak R, Zakov ZN. Nonarteritic anterior ischemic optic neuropathy with macular edema: visual improvement and fluorescein angiographic characteristics. *J Neuro-Ophthalmol* 1998;18:166-168.
72. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 1998;126: 362-372.
73. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 1998;125:779-796.
74. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 1998;125:767-778.
75. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 1998;125:745-766.
76. Parnes RE, Zakov ZN, Novak MA, Rice TA. Vitrectomy in patients with decreased visual acuity secondary to asteroid hyalosis. *Am J Ophthalmol* 1998;125:703-704.
77. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. *Ophthalmology* 1998;105:11-23.
78. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.

79. Kertes PJ, Wafapoor H, Peyman GA, Calixto Jr N, Thompson H, Vitreon Collaborative Study Group. The management of giant retinal tears using perfluoroperhydrophenanthrene. *Ophthalmology* 1997;104:1159-1165.
80. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group. Clear cell differentiation in choroidal melanoma. COMS report no. 8. *Arch Ophthalmol* 1997;115:894-898.
81. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 1997;115:1537-1544.
82. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS Report No. 4. *Arch Ophthalmol* 1997;115:886-893.
83. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.
84. Soheilian M, Peyman GA, Wafapoor H, Navarro GC, Thompson H, the Vitreon Study Group. Surgical management of traumatic retinal detachment with perfluorocarbon liquid. *Int Ophthalmol* 1996-1997;20:241-249.
85. Wells CG, Bradford RH, Fish GE, Straatsma BR, Hawkins BS for the COMS Group. Choroidal melanomas in American Indians. *Arch Ophthalmol* 1996;114:1017-1018.
86. Chern KC, Meisler DM, Hall GS, Meyers SM, Foster RE, Zakov ZN, Lowder CY. Bacterial contamination of anaerobic vitreous cultures: using techniques employed for endophthalmitis. *Curr Eye Res* 1996;15:697-699.
87. Verma LK, Peyman GA, Wafapoor H, Greve MD, Millsap CM, Adile SL. An analysis of posterior segment complications after vitrectomy using the perfluorocarbon perfluoroperhydrophenanthrene (Vitreon). Vitreon Collaborative Study. *Ophthalmic Surg* 1995;26:29-33.
88. Zegarra H, Zakov ZN, Lamkin JC, Addiego R, Singerman LJ. Laser therapy for retinal vein occlusions. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, p.140, 1995.
89. Carroll BF, Peyman GA, Mehta NJ, Millsap CM, Greve MD, Dunlap WA, Lee KJ, Ma PE for the Vitreon Study Group. Repair of retinal detachment associated with proliferative vitreoretinopathy using perfluoroperhydrophenanthrene (Vitreon). *Can J Ophthalmol* 1994;29:66-69.
90. Schachat AP for the Collaborative Ocular Melanoma Study Group. Management of uveal melanoma: a continuing dilemma. [Letter] *Cancer* 1994;74:3073-3075.

91. Kalenak JW, Zakov ZN. Presumed sudden leakage of a pilocarpine ocusert and rhegmatogenous retinal detachment. *J Glaucoma* 1994;3:152-153.
92. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. *Controlled Clin Trials* 1993;14:362-391.
93. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS Report No. 2. In Franklin RM (ed). *Proceedings of the Symposium on Retina and Vitreous, New Orleans Academy of Ophthalmology*. New York: Kugler Publications, 1993, pp 181-190.
94. Zakov ZN. Endoftalmilerde ve travmalarda vitrektomi. *Retina-Vitreus*, Cilt 1, Sayı 2, Aralık 1993, p. 122.
95. Lowder CY, Foster RE, Meisler DM, Zakov ZN. Combined extracapsular cataract extraction, posterior chamber intraocular lens implantation, and pars plana vitrectomy. *Ophthalmic Surg* 1993;24:446-452.
96. Foster RE, Lowder CY, Meisler DM, Zakov ZN. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients. *Ophthalmology* 1992;99:1234-1241.
97. Romania A, Zakov ZN, Church JM, Jagelman DG. Retinal pigment epithelium lesions as a biomarker of disease in patients with familial adenomatous polyposis. A follow-up report. *Ophthalmology* 1992;99:911-913.
98. Heyen F, Jagelman DG, Romania A, Zakov ZN, Lavery IC, Fazio VW, McGannon E. Predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis. *Dis Colon Rectum* 1990;33:1003-1008.
99. Zakov ZN. Managing diabetic retinopathy. *Cleve Clin J Med* 1990;57:609-612.
100. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM for the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. *Am J Ophthalmol* 1990;110:527-534.
101. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 1990;108:1268-1273.
102. Schachat AP, Markowitz JA, Hawkins BS, Fine SL, Collaborative Ocular Melanoma Study Group. Nonocular cancers in patients with choroidal melanoma. [Letter] *Ophthalmology* 1990;97:837-838.

103. Varley GA, Meisler DM, Benes SC, McMahon JT, Zakov ZN, Fryczkowski AF. Hibiclens keratopathy. A clinicopathologic case report. *Cornea* 1990;9:341-346.
104. Perkovich BT, Zakov ZN, Berlin LA, Weidenthal D, Avins LR. An update on multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Retina* 1990;10:18-26.
105. Ambler JS, Meisler DM, Zakov ZN, Hall GS, Spech TJ. Endogenous Mycobacterium chelonae endophthalmitis. *Am J Ophthalmol* 1989;108:338-339.
106. Collaborative Ocular Melanoma Study Steering Committee. Failure of pre-enucleation radiation to decrease uveal melanoma mortality. *Am J Ophthalmol* 1989;107:440-441.
107. Romania A, Zakov ZN, McGannon E, Schroeder T, Heyen F, Jagelman DG. Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. *Ophthalmology* 1989;96:879-884.
108. Gardner TW, Norris JL, Zakov ZN, Williams GW. A survey of intraocular gas use in North America. *Arch Ophthalmol* 1988;106:1188-1189.
109. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA, Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmology* 1988;95:1000-1004.
110. Kincaid MC, Folberg R, Torczynski E, Zakov ZN, Shore JW, Liu SJ, Planchard T, Weingeist TA. Complications after proton beam therapy for uveal malignant melanoma. *Ophthalmology* 1988;95:982-991.
111. McAllister IL, Meyers SL, Zegarra H, Gutman FA, Zakov ZN, Beck GJ. Comparison of pneumatic retinopexy with alternative surgical techniques. *Ophthalmology* 1988;95:877-883.
112. Berlin LA, Zakov ZN. Ultrasonographic evaluation of hemorrhagic choroidal detachments. In Ossoinig C (ed). *Ophthalmic Echography, Documenta Ophthalmologica Proceedings Series 48*. Dordrecht: M. Nijhoff/W. Junk Publishers, 1987, pp. 313-318.
113. Meisler DM, Zakov ZN, Bruner WE, Hall GS, McMahon JT, Zachary AA, Barna BP. Endophthalmitis associated with sequestered intraocular Propionibacterium acnes. *Am J Ophthalmol* 1987;104:428-429.
114. Meisler DM, Palestine AG, Vastine DW, Demartini DR, Murphy BF, Reinhart W, Zakov ZN, McMahon JT, Cliffl T. Propionibacterium endophthalmitis after extracapsular cataract extraction and intraocular lens implantation. *Am J Ophthalmol* 1986;102:733-739.

115. Cole EL, Zakov ZN, Meisler DM. Cutaneous malignant melanoma metastatic to the vitreous. *Arch Ophthalmol* 1986;104:98-101.
116. Stern RM, Zakov ZN, Meisler DM, Hall GS, Martin, A. Endogenous Pseudoallescheria boydii endophthalmitis. *Cleve Clin Quarterly* 1986; 53:197-203.
117. Rabon RJ, Zakov ZN, Meyers SM, Wilbourn AJ. Ulnar nerve mononeuropathies after face-down positioning. *Am J Ophthalmol* 1986;102:125.
118. Beauchamp GR, Meisler DM, Greaves A, Zakov ZN, McMahon JT. Corneal melanocytes in aniridia. *Arch Ophthalmol* 1986;104:799-800.
119. Bale AE, Ludwig IH, Effron LA, Zakov ZN. Linkage between the genes for Wolfram Syndrome and Brachydactyly E. (Letter to the Editor). *Am J Med Genetics* 1985;20:733-734.
120. Fung WD, Zakov ZN, et al. Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized Investigation. *Ophthalmology* 1985;92:1102-1111.
121. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Am J Ophthalmol* 1985;100:560-569.
122. Preslan M, Beauchamp GR, Zakov ZN. Congenital glaucoma and retinal dysplasia. *J Ped Ophthalmol Strabismus* 1985;22:166.
123. Effron L, Zakov ZN, Tomsak RL. Neovascular glaucoma as a complication of Wyburn-Mason syndrome. *J Clin Neuro-Ophthalmol* 1985;5:95-98.
124. Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Possible herpes simplex retinitis. *Ophthalmology* 1984;51:1659.
125. Rockwood EJ, Meyers SM, Meisler DM, Zakov ZN, Langston RHS. Treatment of selected cases of pupillary block with YAG laser iridotomies. (Letter to the Editor). *Ophthalmic Surg* 1984;15:968.
126. Rockwood EJ, Zakov ZN, Bay JW. Combined malignant lymphoma of the eye and central nervous system (reticulum cell sarcoma). A report of three cases. *J Neurosurg* 1984;61:369-374.
127. Zakov ZN, Berlin LA, Gutman FA. Ultrasonographic mapping of vitreoretinal abnormalities. *Am J Ophthalmol* 1983;96:622-631.
128. Zegarra H, Gutman FA, Zakov ZN, Carim M. Partial occlusion of the central retinal vein. *Am J Ophthalmol* 1983;96:330-337.

129. Aaby AA, Price RL, Zakov ZN. Spontaneously regressing retinoblastoma, retinoma, or retinoblastoma Group O. *Am J Ophthalmol* 1983;96:315-320.
130. Cassen JH, Meisler DM, Zakov ZN, Langston RHS. Donor material for corneal grafting. *Am J Ophthalmol* 1983;95:711-712.
131. Wilhelm JL, Zakov ZN. Choroidal malignant melanoma with liver metastasis prior to enucleation. *Ann Ophthalmol* 1982;14:789-796.
132. Lowder CY, Gutman FA, Zegarra H, Zakov ZN, Lowder JN. Macular and paramacular detachment of the neurosensory retina associated with systemic diseases. *Trans Am Ophthalmol Soc* 1981;Vol. LXXIX.
133. Gutman FA, Zegarra H, Rauer A, Zakov ZN. Photocoagulation in retinal branch vein occlusion. *Ann Ophthalmol* 1981;13:1359-1363.
134. Brockhurst RJ, Albert DM, Zakov ZN. Pathologic findings in familial exudative vitreoretinopathy. *Arch Ophthalmol* 1981;99:2143-2146.
135. Dreyer WB Jr, Zegarra H, Zakov ZN, Gutman FA. Sympathetic ophthalmia. A case report. *Am J Ophthalmol* 1981;93:816-823.
136. Wilhelm JL, Zakov ZN, Hoeltge GA. Erythropheresis in treating retinal detachments secondary to sickle cell retinopathy. *Am J Ophthalmol* 1981;92:582-583.
137. Wilhelm JL, Zakov ZN, Weinstein M., Zegarra H, Berlin LA, Gutman FA. Localization of suspected intraocular foreign bodies with a modified Delta 2020 scanner. *Ophthalmic Surg* 1981;12:633-641.
138. Lowder CY, Tomsak RL, Zakov ZN, Hahn J. Visual loss from pituitary tumor masked by optic nerve drusen. *Neurosurgery* 1981;8:473-476.
139. Gutman FA, Zegarra H, Rauer A, Zakov ZN. Photocoagulation in retinal branch vein occlusion. *Trans Am Ophthalmol Soc* 1980;78:156-166..
140. Sakamoto DK, Zegarra H, Gutman FA, Zakov ZN. Silicone sponge implant in combination with episcleral implant for retinal detachment surgery. *Ophthalmic Surg* 1980;11:217-219.
141. Bienfang DC, Zakov ZN, Albert DM. Severe electrical burn of the eye. *Albrecht von Graefes Arch Klin Ophthalmol* 1980;214:147-153.
142. Lubin JR, Grove A Jr, Zakov ZN, Albert DM. Hepatoma metastatic to the orbit. *Am J Ophthalmol* 1980;89:268-273.

143. Albert DM, Robinson NL, Fulton AB, Zakov ZN, Dryja TP, Puliafito CA, Smith AB, Egant E. Epidemiological investigation of increased incidence of choroidal melanoma. *Int Ophthalmol Clin* 1980;2:71-92.
144. Dryja TP, Zakov ZN, Albert DM. Adenocarcinoma arising from the epithelium of the iris and ciliary body. *Int Ophthalmol Clin* 1980;2:177-190.
145. Zakov ZN, Cook, S.A., Albert DM, Weichselbaum RR. False-positive phosphorus 32 uptake tests in the diagnosis of ocular melanomas. *Int Ophthalmol Clin* 1980;2:117-121.
146. Fulton AB, Craft JL, Zakov ZN, Howard RO, Albert DM. Retinal anomalies in Trisomy 18. *Graefes Arch Ophthalmol* 1980;213:195-205.
147. Albert DM, Puliafito CA, Fulton AB, Robinson NL, Zakov ZN, Dryja TP, Smith AB, Egant E, Leffingwell SS. Increased incidence of choroidal malignant melanoma occurring in a single population of chemical workers. *Am J Ophthalmol* 1980;89:323-337.
148. Zakov ZN, Lewis ML. The vitreous. *Year Book of Ophthalmology* 1979, 223-225.
149. Gragoudas ES, Zakov ZN, Albert DM, Constable IJ. Long-term observations in proton-irradiated monkey eyes. *Arch Ophthalmol* 1979;97:2184-2191.
150. Wong S, Zakov ZN, Albert DM. Scleral and choroidal ossification in a patient with pseudohypoparathyroidism. *Br J Ophthalmol* 1979;63:177-180.
151. Albert DM, Lesser RL, Cykier RC, Zakov ZN. Orbitofacial mucormycosis occurring with deposition of calcium salts of fatty acids. *Br J Ophthalmol* 1979;63:699-703.
152. Stowe GC 3rd, Zakov ZN, Albert DM, Smith TR, Sang DN, Craft JL. Vascular basophilia in ocular and orbital tumors. *Invest Ophthalmol Vis Sci* 1979;18:1068-1075.
153. The Miami Study Group. Cystoid macular edema in aphakic and pseudophakic patients. *Am J Ophthalmol* 1979;88:44-48.
154. Kim E, Zakov ZN, Albert DM, Smith TR, Craft JL. Intraocular reticulum cell sarcoma. A case report and literature review. *Albrecht von Graefes Arch Klin Ophthalmol* 1979;208:167-178.
155. Weichselbaum R, Zakov ZN, Albert DM, Friedman AM, Nove J, Little JB. New findings in the chromosome 13 long arm deletion syndrome and retinoblastoma. *Ophthalmology* 1979;86:1191-1198.
156. Albert DM, Zakov ZN, Smith TR. Late diagnosis of choroidal malignant melanoma in eyes with clear media and low visual acuity. *Ophthalmology* 1979;86:1037-1047.

157. Zakov ZN, Rich L, Zegarra H, Gutman FA. Differential diagnosis of preretinal neovascularization. *Persp Ophthalmol* 1978;2:223-231.
158. Zakov ZN, Dohlman CH, Perry HD, Albert DM. Corneal donor material selection. *Am J Ophthalmol* 1978;86:605-610.
159. Stowe CG, Zakov ZN, Albert DM. Central retinal vascular occlusion associated with oral contraceptives. *Am J Ophthalmol* 1978;86:798-801.
160. Zakov ZN, Smith TR, Albert DM. False-positive 32p uptake test. *Arch Ophthalmol* 1978;96:2240-2243.
161. Gunderson T, Smith TR, Zakov ZN, Albert DM. Choroidal melanocytic tumor observed for 41 years before enucleation. *Arch Ophthalmol* 1978;96:2089-2092.
162. Zakov ZN, Lewis ML. Iris fluorescein angiography in diabetic vitrectomy patients. *Albrecht von Graefes Arch Klin Ophthalmol* 1978;206:17-24.
163. Zakov ZN, Berlin AJ, Machemer CJ. Blepharoptosis as a complication of soft lens wear. *Contact and Intraocular Lens Med J* 1977;3:22-23.
164. Gutman FA, Zakov ZN, Zegarra H. Retinal branch vein occlusion. *Persp Ophthalmol* 1977;1:2-8.
165. Gutman FA, Zegarra H, Zakov ZN. Temporal retinal branch vein occlusion. Correlation of fluorescein angiography and visual prognosis. In Cant JS (ed.). *Vision and Circulation*, Third William MacKenzie Memorial Symposium. St. Louis: CV Mosby Co., 1976.
166. Cohen DN, Zakov ZN, Salanga VD, Dohn DF. Raeder's paratrigeminal syndrome. A new etiology. *Am J Ophthalmol* 1975;79:1044-1049.
167. Cohen DN, Zakov ZN. The diagnosis of Adie's pupil using 0.0625% pilocarpine solution. *Am J Ophthalmol* 1975;79:883-884.

Abstracts

1. Coney JM, Gurelik G, Zakov NZ. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *ARVO Abstracts* 2003; Program # 3982; Poster# B685.
2. Maguire MG, Fine SL, Maguire AM, D'Amato RJ, Singerman LJ, the AMDATS Research Group. Results of the Age-related Macular Degeneration and Thalidomide Study (AMDATS). *ARVO Abstracts*, #1255, 2001.

3. Hollick RA, Reynolds SM for the COMS Group: The impact of adding new clinical centers during the course of a clinical trial for a rare condition. *Controlled Clin Trials* 19(3, suppl):69, 1998.
4. Imesch PD, Levitt BT, Albert DM for the COMS Group: Apoptosis in intraocular and metastatic melanomas. *Invest Ophthalmol Vis Sci* 39(4,suppl):414, 1998.
5. Zakov ZN. Intraocular lens compatibility with vitreous substitutes. *XXVIIIth International Congress of Ophthalmology*. Amsterdam, p. 55, 1998.
6. Matthews GP, Purohit SS, Zakov ZN. Repair of primary rhegmatogenous retinal detachment by pneumatic buckle *Invest Ophthalmol Vis Sci* 39 (4, suppl):207 (abstract #969), 1998.
7. Moy CS, Melia BM, Gutierrez PR, Mangione CM for the COMS-QOLS Group: Assessment of visual functioning with the NEI-VFQ in patients with choroidal melanoma: a pilot study. *Invest Ophth Vis Sci* 38:S841, 1997.
8. Moy CS, Melia BM, Gutierrez PR, Mangione CM for the COMS-QOLS Group. Validity of the Visual Functioning Questionnaire in patients with choroidal melanoma: a pilot study. *Quality of Life Res* 6:693, 1997.
9. Earle JD, Schachat AP, Fine SL, Hawkins BS, Diener-West M for the COMS. Three-year results of enucleation surgery with or without preoperative radiation therapy (PERT) in the prospective randomized Collaborative Ocular Melanoma Study (COMS) large tumor trial. *Int J Rad Oncol Biol Phys* 39(2, Suppl): 159, 1997.
10. Manos KS, Moy CS for the COMS-QOLS Group. Incorporating a quality of life assessment into an ongoing multi-center clinical trial: problems and recommendations. *Controlled Clin Trials* 18(3, suppl):104, 1997.
11. Manos KS, Hollick RA for the COMS Group. Does workspace affect coordinator performance in a randomized clinical trial? *Controlled Clin Trials* 17 (2, suppl):134, 1996.
12. Melia BM, Diener-West M, Folk JC, Bennett SR, Montague PR, Weingeist TA, for the COMS Group. Mortality and tumor growth in patients with choroidal melanoma: a report from the COMS Group. *Invest Ophthalmol Vis Sci* 36 (4, suppl):1036, 1995.
13. Chern KC, Meisler DM, Hall GS, Meyers SM, Foster RE, Lowder CY, Zakov ZN. Bacterial contamination of vitreous cultures using techniques employed for endophthalmitis. *Invest Ophthalmol Vis Sci* 36 (suppl):790, 1995.
14. Romania A, Zakov ZN. Church JM, Jagelman DG, Heyen F, McGannon EA. Three-year follow-up of patients with familial adenomatous polyposis. *Ophthalmology* 101:171S, 1994.

15. Coates TC, Hawkins BS, for the COMS Group. (Un)Predictability of accrual in randomized clinical trials. *Controlled Clin Trials* 16 (suppl): 83, 1995.
16. Umlas J, Albert D, Diener-West M, for the Collaborative Ocular Melanoma Study Group. Correlation of transillumination size and microscopic measurement of choroidal melanoma. *Invest Ophthalmol Vis Sci* 35:1925, 1994.
17. Albert DM, Green WR, Grossniklaus HE, Diener-West M for the Collaborative Ocular Melanoma Study Group. Histopathologic review of 1,091 uveal melanomas. *Invest Ophthalmol Vis Sci* 35:1925, 1994.
18. Montague PR, Melia M, Weingeist TA, COMS Group. Evaluation of radiation retinopathy with color photography alone vs color photography with fluorescein angiography. *Invest Ophthalmol Vis Sci* 35:1722, 1994.
19. Manos KS, Moy CS for the COMS Group. Phantom or real? Verification of nonrandomized patients evaluated for randomized clinical trials of a rare disease. *Controlled Clin Trials* 14:441, 1993.
20. Coates TC for the COMS Coordinating Center: Archiving and material storage for a long-term clinical trial. *Controlled Clin Trials* 14:448, 1993.
21. Moy CS for the COMS Group. Factors predictive of choice of treatment among patients with choroidal melanoma. *Invest Ophthalmol Vis Sci* 34:967, 1993.
22. Collaborative Ocular Melanoma Study Group. Five-year progress report from the Collaborative Ocular Melanoma Study. *Ophthalmology* 99 (suppl):158, 1992.
23. Kirkwood JM, Earle JD, Fine SL, Hawkins BS, Straatsma BR, Mowery RL for the COMS Group. Five-year progress report: The Collaborative Ocular Melanoma Study. *Proc ASCO* 11:349, 1992.
24. Hawkins BS, Fine SL, Straatsma BR, Mowery RL, Earle JD for the COMS Group. Five-year progress report from the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 33 (4, suppl):1254, 1992.
25. Diener-West M, Willis DM, Hawkins BS for the Collaborative Ocular Melanoma Study Group. Sociodemographic factors of patient participation in randomized trials. Findings from the COMS. *Invest Ophthalmol Vis Sci* 32 (4, suppl):980, 1991.
26. Markowitz JA, Willis DM, Collaborative Ocular Melanoma Study Research Group. Is standardization possible in a multicenter clinical trial in which 45 medical centers and 500 clinical professionals are involved? *Controlled Clin Trials* 11:289, 1990.
27. Meyers S, Lowder CY, Meisler DM, Zakov ZN. Vitrectomy in young uveitis patients. *Invest Ophthalmol Vis Sci* 31 (suppl):141, 1990.

28. Heyen F, Jagelman DG, Lavery IC, Fazio VW, Romania A, Zakov ZN, McGannon E. The predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis. *ASCRS Annual Convention*, 1989.
29. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study. *Ophthalmology* 95 (suppl):190, 1988.
30. Markowitz JA, Hawkins BS, Diener-West M, Schachat AP, Fine SL, Straatsma BR, Earl JD, Collaborative Ocular Melanoma Study Group. Baseline characteristics of the first 450 cases evaluated for the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 29 (suppl):120, 1988.
31. Diener-West M, Hawkins BS, Fine SL for the COMS Research Group. Challenges in designing and conducting a clinical trial for a rare condition. *Invest Ophthalmol Vis Sci* 28: (suppl): 393, 1987.
32. Meisler DM, Zachary AA, Braun WE, Barna BP, Hall GS, Zakov ZN. Association of DQW1 with uveitis following cataract extraction. *Invest Ophthalmol Vis Sci* 28: (suppl): 43, 1987.
33. COMS Group. The Collaborative Ocular Melanoma Study. *Ophthalmology* 93 (suppl):135, 1986.
34. Fine SL, Straatsma BR, Hawkins BS, Schachat AP, Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 27 (3, suppl):312, 1986.
35. Cole EL, Zakov ZN, Hack BG, Meisler DM, Zegarra H, Berlin AJ, Berlin LA, Ellsworth RH, Chang S. The varied representation of cutaneous malignant melanoma metastatic of the eye and orbit. *Ophthalmology* 92:101S, 1985.
36. Rosenfeld SI, Culbertson WW, Meisler DM, Zakov ZN, Cliffel TP, Rabon R, Langston RHS. Phacoanaphylactic uveitis following extracapsular cataract extraction with posterior chamber lens implant. *Ophthalmology* 92:60S, 1985.
37. Fitzgibbon EJ, Price RL, Zegarra H, Zakov ZN. Complications after lensectomy surgery for congenital cataract. *Invest Ophthalmol Vis Sci* 25 (suppl):172, 1983.
38. Zakov ZN, Tubbs RR, Lamping A., Albert DM, Robinson N. Immunohistochemical findings in giant cell arteritis. *Invest Ophthalmol Vis Sci* (suppl): 246, 1983.
39. Albanese U, Zakov ZN, Zegarra H. Xenon endophotocoagulation and neovascular glaucoma in postvitrectomy diabetic eyes. *Invest Ophthalmol Vis Sci* (suppl), March 1983, p. 58.
40. Zegarra H, Gutman FA, Zakov ZN, Carim M. Partial central retinal vein occlusion. *Invest Ophthalmol Vis Sci* (suppl), March 1981, p. 142.

41. Fulton AB, Craft JL, Zakov ZN. Retinal anomalies in Trisomy 18. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 44.
42. Ricker DP, Zakov ZN, Albert DM, Craft JL, Klepach GL, Keltner JL. Studies of the pathogenesis and morphology of temporal arteritis. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 205.
43. Zakov ZN, Gragoudas ES, Albert DM, Constable IJ. Long-term observation in proton-irradiated monkey eyes. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 45.

National Technical Information Service

1. Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures. PB95-179693, National Technical Information Service, Springfield, Virginia, January 1995.
2. Collaborative Ocular Melanoma Study Group. COMS Study Forms Book, PB91-217315, National Technical Information Service, Springfield, Virginia, May 1991.

Book Reviews

1. *Practical Atlas of Retinal Disease and Therapy*. Editor: William R. Freeman. Ocular Surgery News, May 1, 1993.
2. *Fluorescein Angiography*. Authors: Joseph W. Berkow, David H. Orth, and James S. Kelly. Ocular Surgery News, November 15, 1992
3. *Eye Trauma*. Editors: BJ Shingleton, PS Hersh, and KR Kenyon. Ocular Surgery News, March 15, 1992
4. *Laser Surgery of the Posterior Segment*. Authors: Steven M. Bloom and Alexander J. Brucker. Ocular Surgery News, August 15, 1991
5. *Retinal and Choroidal Manifestations of Systemic Diseases*. Editors: L. Singerman and L. Jampol. Ocular Surgery News, July 15, 1991
6. *Ophthalmic Lasers*. Author: Francis A. L'Esperance, Jr. Cleve Clin J Med, March-April, 1991
7. *Retinal Pigment Epithelium*. Editors: M. Zingirian and F. Cardillo Piccolino. Ocular Surgery News, January 15, 1991.
8. *Retina*. Editor-in-Chief: Steven J. Ryan. Cleve Clin J Med 57:492, 1990.
9. *Proliferative Vitreoretinopathy*. Editors: K. Heiman and P. Wiedemann. Ocular Surgery News, April 15, 1990

10. *New Microsurgical Concepts II, Vol. 18*. Editors: J. Draeger and R. Winter. Ocular Surgery News, March 1, 1990
11. *Diabetes and Its Ocular Complications*. Authors: William E. Benson, Gary C. Brown, and William Tasman. Cleve Clin J Med 57:100, 1990.
12. *Stereoscopic Atlas of Macular Disease. Diagnosis and Treatment*. Author: J. Donald M. Gass. Cleve Clin J Med 55:571, 1988.
13. *Handbook of Ophthalmology*. Authors: Thomas W. Gardner and David E. Shoch. Cleve Clin J Med 55:569, 1988.